Advice

In the absence of a submission from the holder of the marketing authorisation.

gonapeptyl depot is not recommended for use within NHS Scotland for the treatment of advanced, hormone-dependent prostate carcinoma.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHS Scotland.

Download detailed advice29KB (PDF)

Download

Medicine details

Medicine name:
Gonapeptyl depot 3.75mg
SMC ID:
269/06
Indication:
Advanced, hormone-dependent prostate carcinoma
Pharmaceutical company
Ferring Pharmaceuticals Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Non submission
Status
Not recommended
Date advice published
08 May 2006